Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01499927
Other study ID # FZMI-KEK-ZH-Nr. 2010-0457
Secondary ID
Status Completed
Phase N/A
First received November 15, 2011
Last updated December 18, 2013
Start date January 2012
Est. completion date December 2012

Study information

Verified date December 2013
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.


Description:

Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs, risk of complications as well as higher workload on nursing. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.


Recruitment information / eligibility

Status Completed
Enrollment 74766
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion criteria:

- all in-patients in treatment with an intravenous antiinfective for >60h,

- hospitalized in a ward with computerized physician order entry (cpoe)

Exclusion criteria:

- outpatients,

- ward without cpoe,

- no intravenous antiinfective treatment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research


Related Conditions & MeSH terms

  • Infection as Complication of Medical Care

Intervention

Other:
electronic reminders
Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders

Locations

Country Name City State
Switzerland University Hospital Zurich, Center for Clinical Research Zurich ZH

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary duration of intravenous antiinfective therapy until switching 1 year No
Secondary costs (per year, per day and patient) 1 year No
Secondary defined daily doses (per 100 days) 1 year No
Secondary duration of hospitalization 1 year No
Secondary ratio of narrow to broad-spectrum antibiotics 1 year No
Secondary requests for consultations 1 year No